Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Change in Accured Expenses data on file, last reported at -$15.3 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 117.71% year-over-year to -$15.3 million in Q2 2026; TTM through May 2026 was $6.2 million, a 58.36% decrease from a year earlier, with the FY2025 full-year figure at $17.3 million, up 46.5% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at -$15.3 million, down from $4.1 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for NRIX reached as high as $11.0 million in Q4 2025 and fell as low as -$15.3 million in Q2 2026.
• Historically, Change in Accured Expenses has averaged $1.6 million across 5 years, with a median of $3.4 million in 2022.
• Across the five-year window, Change in Accured Expenses surged 314.68% in 2022 and sank 402.88% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.3 million in 2022, then retreated by 6.71% to $3.1 million in 2023, then surged by 193.46% to $9.0 million in 2024, then grew by 22.36% to $11.0 million in 2025, then tumbled by 238.14% to -$15.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$15.3 million in Q2 2026, $4.1 million in Q1 2026, and $11.0 million in Q4 2025.